Summary of expression of SPARC protein in cutaneous vascular neoplasms and mimickers |
| |
| Affiliation: | 1. Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;2. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;3. Department of Pathology, The University of Texas Health Science Center, Houston, TX, USA;1. Private Buca Medical Center Pathology Department, Izmir, Turkey;2. Private Tinaztepe Hospital Microbiology Department, Izmir, Turkey;1. Clinic for Urology and Paediatric Urology, University Hospital of Bonn, Sigmund-Freud Str. 25, 53127 Bonn, Germany;2. Institute of Pathology, University Hospital of Bonn, Sigmund-Freud Str. 25, 53127 Bonn, Germany;1. Department of Hematology, People''s Liberation Army Center of Hematologic Disorders, Xijing Hospital, Fourth Military Medical University, Xi''an 710032, China;2. Department of Pathology, Xijing Hospital, Fourth Military Medical University, Xi''an 710032, China |
| |
| Abstract: | BackgroundSerum protein acidic and rich in cysteine (SPARC) is a matricellular glycoprotein, which regulates cell proliferation and facilitates intracellular transport of albumin bound particles including chemotherapeutic agents such as Nab-paclitaxel/ABI-007. Therefore the presence of SPARC may achieve higher intra-tumoral drug concentration with lower dosage and thus reduce systemic side-effects. Several trials of ABI-007, in melanoma, show promising clinical activity.DesignFifty-four cases of dermal based neoplasms were retrieved including 24 angiosarcomas (AS), 10 hemangiomas, 9 nodular melanomas, 4 Kaposi sarcomas (KS), 3 leiomyosarcomas (LMS), 3 atypical fibroxanthomas (AFX) and 1 spindle cell squamous cell carcinoma (SSCC). SPARC immunohistochemistry (IHC) was performed with a mouse monoclonal antibody.ResultsSPARC expression was detected in a majority of AS (17/24), melanomas (8/9), AFX (3/3), LMS (3/3) and KS (4/4) with some expression in hemangiomas (3/10), while being negative in SSCC (0/1); and was significantly associated with tumor group (p = 0.017). Although a significant difference in overall survival was observed between SPARC expression groups (positive vs. negative) for all patients, there was no significant difference noted among angiosarcoma patients.ConclusionWe have confirmed the presence of SPARC expression in melanoma, KS, LMS and AS and also detected it for the first time in AFX. Since paclitaxel has shown some effectiveness in AS, melanoma and KS, ABI-007 could also be beneficial in these patients. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
